^
Association details:
| Biomarker: | HR positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | atamparib (RBN-2397) (PARP7 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A first-in-human phase 1 study of a novel PARP7 inhibitor RBN-2397 in patients with advanced solid tumors.
Published date:
05/19/2021
Excerpt:
Patients (pts) with advanced solid tumors were treated with RBN-2397 on either a continuous or 14-of-21-day...1 pt with HR+, HER2- breast cancer achieved a confirmed PR at 100 mg and 8 pts had SD for ≥18 weeks…
DOI:
10.1200/JCO.2021.39.15_suppl.3000
Trial ID: